in this issue
Regions :: India/Pakistan
Ipca suspends API shipments to US
8:59 AM MDT | July 25, 2014 | Deepti Ramesh
Ipca Laboratories (Mumbai), a manufacturer of formulations and active pharmaceutical ingredients (APIs), says it has decided to temporarily suspend API shipments from its manufacturing facility at Ratlam, India, to the United States in order to resolve issued identified during a recent US FDA inspection of that facility. Ipca received certain inspection observations in Form 483 from FDA. The voluntary suspension will also impact the company's formulations export business to the US market, since Ipca's formulations facilities at Piparia and Indore, India, use APIs...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee